- Home
- REFI vs CVRX Comparison
REFI vs CVRX Comparison
Compare REFI & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFI
- CVRX
- Stock Information
- Founded
- REFI 2021
- CVRX 2000
- Country
- REFI United States
- CVRX United States
- Employees
- REFI N/A
- CVRX N/A
- Industry
- REFI Real Estate Investment Trusts
- CVRX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- REFI Real Estate
- CVRX Health Care
- Exchange
- REFI Nasdaq
- CVRX Nasdaq
- Market Cap
- REFI 255.6M
- CVRX 253.2M
- IPO Year
- REFI 2021
- CVRX 2021
- Fundamental
- Price
- REFI $12.68
- CVRX $9.91
- Analyst Decision
- REFI Strong Buy
- CVRX Buy
- Analyst Count
- REFI 3
- CVRX 7
- Target Price
- REFI $20.00
- CVRX $13.17
- AVG Volume (30 Days)
- REFI 102.5K
- CVRX 286.4K
- Earning Date
- REFI 11-04-2025
- CVRX 11-05-2025
- Dividend Yield
- REFI 16.57%
- CVRX N/A
- EPS Growth
- REFI N/A
- CVRX N/A
- EPS
- REFI 1.69
- CVRX N/A
- Revenue
- REFI $54,287,847.00
- CVRX $55,969,000.00
- Revenue This Year
- REFI $11.43
- CVRX $11.32
- Revenue Next Year
- REFI $4.75
- CVRX $18.58
- P/E Ratio
- REFI $7.34
- CVRX N/A
- Revenue Growth
- REFI N/A
- CVRX 18.44
- 52 Week Low
- REFI $11.85
- CVRX $4.30
- 52 Week High
- REFI $16.29
- CVRX $18.55
- Technical
- Relative Strength Index (RSI)
- REFI 48.94
- CVRX 57.13
- Support Level
- REFI $11.85
- CVRX $8.37
- Resistance Level
- REFI $12.97
- CVRX $9.58
- Average True Range (ATR)
- REFI 0.27
- CVRX 0.83
- MACD
- REFI -0.01
- CVRX -0.02
- Stochastic Oscillator
- REFI 71.43
- CVRX 72.12
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About CVRX CVRx Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.